Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

The HD mutation does not alter neuronal death in the striatum of Hdh(Q92) knock-in mice after mild focal ischemia.

Namura S, Hirt L, Wheeler VC, McGinnis KM, Hilditch-Maguire P, Moskowitz MA, MacDonald ME, Persichetti F.

Neurobiol Dis. 2002 Oct;11(1):147-54.

PMID:
12460554
2.

Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ.

J Neurosci. 2003 Mar 15;23(6):2193-202.

3.

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R.

Hum Mol Genet. 2007 Aug 1;16(15):1845-61. Epub 2007 May 21.

4.

Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.

Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, Ellerby LM.

Cell Death Differ. 2004 Apr;11(4):424-38.

5.

Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.

Bizat N, Hermel JM, Boyer F, Jacquard C, Créminon C, Ouary S, Escartin C, Hantraye P, Kajewski S, Brouillet E.

J Neurosci. 2003 Jun 15;23(12):5020-30. Erratum in: J Neurosci. 2003 Oct 29;23(30):9960.

6.

Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF.

J Neurosci. 2002 Sep 15;22(18):8266-76.

7.

The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin.

Auerbach W, Hurlbert MS, Hilditch-Maguire P, Wadghiri YZ, Wheeler VC, Cohen SI, Joyner AL, MacDonald ME, Turnbull DH.

Hum Mol Genet. 2001 Oct 15;10(22):2515-23.

8.

BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.

García-Martínez JM, Pérez-Navarro E, Xifró X, Canals JM, Díaz-Hernández M, Trioulier Y, Brouillet E, Lucas JJ, Alberch J.

J Neurosci Res. 2007 Sep;85(12):2756-69.

PMID:
17387706
9.

Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice.

Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, Hersch S, Auerbach W, Joyner AL, MacDonald ME.

Hum Mol Genet. 2000 Mar 1;9(4):503-13.

10.

Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.

Xifró X, García-Martínez JM, Del Toro D, Alberch J, Pérez-Navarro E.

J Neurochem. 2008 Jun;105(5):1596-612. doi: 10.1111/j.1471-4159.2008.05252.x. Epub 2008 Jan 24.

11.
12.

Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice.

Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, Friedlander RM, Gusella JF, Vonsattel JP, Borchelt DR, MacDonald ME.

Hum Mol Genet. 2002 Mar 15;11(6):633-40.

13.

Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.

Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M.

J Neurosci. 1999 Feb 1;19(3):964-73.

14.

Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.

Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel KB, Chase K, Aronin N, DiFiglia M.

J Neurosci Res. 2010 Jan;88(1):179-90. doi: 10.1002/jnr.22184.

PMID:
19642201
15.

Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Martín-Aparicio E, Yamamoto A, Hernández F, Hen R, Avila J, Lucas JJ.

J Neurosci. 2001 Nov 15;21(22):8772-81.

16.

Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

Li H, Li SH, Yu ZX, Shelbourne P, Li XJ.

J Neurosci. 2001 Nov 1;21(21):8473-81.

17.

Huntingtin is degraded to small fragments by calpain after ischemic injury.

Kim M, Roh JK, Yoon BW, Kang L, Kim YJ, Aronin N, DiFiglia M.

Exp Neurol. 2003 Sep;183(1):109-15.

PMID:
12957494
18.

Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice.

Fossale E, Wheeler VC, Vrbanac V, Lebel LA, Teed A, Mysore JS, Gusella JF, MacDonald ME, Persichetti F.

Hum Mol Genet. 2002 Sep 15;11(19):2233-41.

19.
20.

Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.

Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.

Hum Mol Genet. 2006 Jun 15;15(12):2015-24. Epub 2006 May 10.

Items per page

Supplemental Content

Write to the Help Desk